HC Wainwright Reiterates Buy Rating for Ikena Oncology (NASDAQ:IKNA)

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 127.27% from the company’s previous close.

Separately, Wedbush reiterated a “neutral” rating and set a $2.00 price target on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Trading Up 0.6 %

Ikena Oncology stock opened at $1.76 on Monday. Ikena Oncology has a 12 month low of $1.22 and a 12 month high of $2.32. The business’s fifty day simple moving average is $1.70 and its two-hundred day simple moving average is $1.64. The company has a market capitalization of $84.93 million, a price-to-earnings ratio of -1.43 and a beta of 0.48.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. On average, equities research analysts predict that Ikena Oncology will post -1.03 EPS for the current year.

Hedge Funds Weigh In On Ikena Oncology

A number of hedge funds have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Ikena Oncology during the 2nd quarter valued at about $30,000. BBR Partners LLC purchased a new position in shares of Ikena Oncology in the 2nd quarter worth $33,000. AQR Capital Management LLC purchased a new stake in Ikena Oncology during the second quarter valued at $36,000. Acadian Asset Management LLC lifted its stake in shares of Ikena Oncology by 15.2% in the 2nd quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after purchasing an additional 42,931 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ikena Oncology during the second quarter valued at approximately $75,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.